SB1973 (Treat and Reduce Obesity Act of 2025) amends Title XVIII of the Social Security Act to reorganize how Medicare supports prevention and treatment of obesity in adults. The bill instructs the Secretary of Health and Human Services to modify coverage rules so more clinicians and approved community programs can furnish Medicare-covered obesity interventions, and it requires a statutory reporting stream to Congress about implementation.
The measure also makes a targeted change to prescription-drug coverage rules to permit Medicare drug plans to cover medications when used to treat obesity or for weight-loss management in overweight beneficiaries with related comorbidities. The combination of coverage and coordination changes is designed to expand access to non-surgical obesity care under Medicare and signal a federal effort to integrate clinical and community-based approaches.
At a Glance
What It Does
The bill authorizes the Secretary to expand the set of clinicians and approved community programs eligible to furnish Medicare-covered intensive behavioral therapy for obesity and requires coordination with referring physicians. It also amends Part D eligibility so certain drugs used for obesity or weight-loss management fall within drug plan coverage rules.
Who It Affects
Medicare beneficiaries with obesity or overweight plus comorbidities, primary care and non-primary care physicians, advanced practice clinicians (PAs, NPs, clinical nurse specialists), clinical psychologists, registered dietitians/nutrition professionals, CMS and Medicare Part D plan sponsors, and community-based lifestyle programs.
Why It Matters
If implemented, the bill shifts delivery toward a broader workforce and community-based providers, and it removes a legal roadblock that has limited Medicare Part D coverage of anti-obesity medications—changes that could increase utilization, alter provider workflows, and affect Medicare program spending and plan formularies.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill inserts a new paragraph into the Medicare statute that expands who may furnish intensive behavioral therapy (IBT) for obesity as a Medicare-covered benefit. Rather than limiting coverage to qualified primary care physicians and practitioners, the Secretary may designate additional physicians, other appropriate health care providers (explicitly listing physician assistants, nurse practitioners, clinical nurse specialists, clinical psychologists, and registered dietitians or nutrition professionals), and evidence-based community lifestyle-counseling programs.
That expansion is permissive—the Secretary remains the decisionmaker about which additional provider types to authorize.
The expansion comes with limits designed to preserve clinical oversight and privacy. For IBT furnished by non-primary-care clinicians or community programs the bill conditions Medicare coverage on (1) a referral from and coordination with a physician or primary care practitioner and (2) delivery in specified settings (an office, hospital outpatient department, or a community-based site that meets federal privacy rules under HIPAA, or other settings the Secretary allows).
The bill also requires the furnishing provider or program to communicate recommendations and treatment plans back to the referring clinician so the care remains integrated.On drugs, the bill alters statutory language governing Part D exclusions so that a drug used to treat obesity, or to manage weight for an overweight beneficiary with at least one related comorbidity, is not blocked by an exclusion referenced in existing law. The change is technical (an amendment to the statutory cross-reference) but consequential: it creates statutory authority for Part D plans to cover certain anti-obesity medications.
That coverage change does not take immediate effect; the bill delays application until plan years beginning two years after enactment.Finally, the bill requires HHS to report to Congress within one year of enactment and then every two years on actions taken to implement the law and on recommendations for better coordination across federal programs related to obesity prevention and care. Those reports are the bill’s primary accountability mechanism and the vehicle for the Secretary to propose operational or regulatory fixes as implementation proceeds.
The Five Things You Need to Know
The bill adds a new paragraph to section 1861(ddd) of the Social Security Act explicitly authorizing the Secretary to cover intensive behavioral therapy furnished by additional clinicians and approved community programs.
Coverage for IBT provided by non-primary-care clinicians or community programs is contingent on a referral from, and coordination with, a physician or primary care practitioner and delivery in an office, hospital outpatient department, or HIPAA-compliant community-based site (or another Secretary-approved setting).
The statute requires the furnishing provider or lifestyle program to communicate any recommendations or treatment plans to the referring clinician to ensure collaborative care.
SB1973 amends the Part D statutory cross-reference so drugs used to treat obesity or for weight-loss management in overweight beneficiaries with one or more related comorbidities may be covered under Medicare Part D; that change applies to plan years beginning two years after enactment.
HHS must submit a report to Congress within one year of enactment and biennially thereafter describing implementation steps and recommending ways to better coordinate HHS and other federal programs related to adult obesity prevention and treatment.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Designates the measure as the "Treat and Reduce Obesity Act of 2025." This is purely a labeling provision; it has no operative effect on policy but identifies the statute for citations and later reference.
Findings
Lists Congress's findings about obesity prevalence, cost, and health risks. While not legally operative, the findings signal legislative intent and provide context the Secretary may cite when developing guidance or rulemaking related to the statute's implementation.
Expands which providers and programs may furnish Medicare-covered intensive behavioral therapy
Adds a new paragraph authorizing the Secretary to cover IBT when furnished by additional physicians (not limited to primary care), other appropriate health care providers (including PAs, NPs, clinical nurse specialists, clinical psychologists, and registered dietitians/nutrition professionals), and evidence-based, community-based lifestyle counseling programs. For non-primary-care clinicians and community programs the amendment conditions coverage on a referral and coordination with a physician or PCP and limits covered settings to offices, hospital outpatient departments, or community sites that meet federal privacy rules (HIPAA), or other Secretary-specified settings. The provision also requires two-way communication so the referring clinician receives treatment recommendations and plans, creating an explicit continuity-of-care duty tied to coverage.
Permits Part D coverage for drugs used to treat obesity or manage weight with comorbidities
Edits the Part D exclusion language by inserting an exception for drugs used to treat obesity or for weight-loss management in overweight beneficiaries with at least one related comorbidity, referencing definitions in section 1861(yy). The textual change removes a statutory barrier that has limited Part D coverage of certain anti-obesity medications. The amendment includes a delayed effective date: it applies to plan years beginning two years after enactment, giving CMS and Part D sponsors lead time to revise formularies and utilization-management policies.
Reporting requirement to Congress
Requires the Secretary of HHS to report to Congress not later than one year after enactment and every two years thereafter on steps taken to implement the Act and on recommendations for better coordination across HHS and other federal agencies related to obesity research, prevention, and clinical care. The content requirement gives the Secretary latitude to propose operational fixes or identify resource needs in future reports.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Medicare beneficiaries with obesity or overweight plus comorbidities — they gain increased access to covered behavioral therapy and a clearer statutory pathway for Part D coverage of obesity medications.
- Non-physician clinicians (physician assistants, nurse practitioners, clinical nurse specialists), clinical psychologists, and registered dietitians/nutrition professionals — the bill explicitly recognizes these providers as potential Medicare-covered suppliers of IBT, creating new revenue opportunities and care roles.
- Evidence-based community lifestyle counseling programs — when approved by the Secretary, these programs can become Medicare-covered sources of IBT, potentially expanding community-clinic partnerships and reimbursable services.
- Manufacturers and distributors of FDA-approved anti-obesity medications — the statutory change opens the door to wider Part D coverage, which could increase demand and market access for covered drugs.
- Primary care clinicians — clearer rules for referral-based, coordinated IBT may help distribute behavioral counseling workload and integrate community resources into chronic care plans.
Who Bears the Cost
- Medicare program and taxpayers — broader coverage for behavioral therapy and medications is likely to increase utilization and program spending, at least initially, with downstream budget impacts on both Part A/B and Part D spending.
- Medicare Part D plan sponsors and PBMs — plans will need to update formularies, utilization management, and benefit designs to incorporate obesity drugs subject to the new statutory allowance, creating administrative and financial adjustments.
- Community-based programs and small providers — to receive Medicare payment these entities may need to meet evidence-based standards and HIPAA privacy requirements, which can impose compliance costs and administrative overhead.
- CMS and HHS — the agencies will face implementation tasks (defining eligible programs, issuing guidance, processing coverage determinations, and preparing required reports) that absorb staff time and may require new resources or rulemaking.
- Referring physicians and primary care practices — increased coordination and required communication from furnishing providers adds documentation and care-management responsibilities that may fall to busy primary care teams.
Key Issues
The Core Tension
The central dilemma is expanding access to evidence-based obesity treatments—by broadening qualified providers and enabling Part D coverage—while containing program spending and ensuring clinical quality; increased access can improve outcomes and reduce downstream costs, but it also risks higher near-term Medicare expenditures and requires robust clinical standards and administrative capacity to prevent misuse or fragmentation of care.
The bill expands access but leaves several operational details unsettled. It authorizes—rather than mandates—the Secretary to designate additional provider types and community programs; how CMS sets qualifying standards, documentation requirements, and billing codes will determine practical access.
The referral-and-coordination requirement preserves clinical oversight but can become a gatekeeping step: if CMS requires strict referral formats or extensive documentation, smaller community programs risk administrative exclusion. The HIPAA-compliance condition protects patient privacy but creates setup and maintenance costs for community sites that previously operated outside health-care billing systems.
On the drug side, the statutory tweak removes a specific exclusion but does not set coverage criteria, utilization-management rules, or duration-of-therapy limits; those will be left to Part D plans and CMS guidance. The two-year delay gives plans time to adjust but also delays patient access.
The bill does not address whether Medicare will require or fund prior authorization controls, step therapy, or specialty-tier cost sharing for high-cost agents (for example, GLP-1 class medications), so plans may still impose access barriers. Finally, broader coverage could materially increase utilization and program costs; absent offsets or explicit budgetary authority, that creates a fiscal trade-off and will likely shape CMS's implementation choices.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.